Filter By:
Sex differences in COVID-19 vaccine confidence in people living with HIV in Canada
Examining attitudes and beliefs towards vaccination against COVID-19 based on sex.
View PublicationStigma, Discrimination and Other Social-Structural Factors Associated with Barriers to Counselling or Therapy among Women Living with HIV Who have Experienced Violence in Metro Vancouver, Canada
Examining social and structural factors associated with barriers to counselling or therapy amongst women living with HIV who experienced lifetime physical and/or sexual violence.
View PublicationAssociations of Early Prolonged Secondary Amenorrhea in Women With and Without HIV
Determining whether women with HIV have a higher lifetime prevalence of amenorrhea and whether this is independently associated with HIV and/or other variables.
View PublicationCoronavirus disease 2019 outcomes in a population-based cohort of people with HIV and a matched cohort of people without HIV during Omicron variant waves
Estimating rates of Omicron-associated COVID-19 outcomes in a population-based cohort of people with HIV in Ontario, Canada, compared with a matched cohort of people without HIV
View PublicationMetabolic dysfunction‐associated steatohepatitis exhibits sex differences in people with HIV
To investigate sex‐based differences in metabolic dysfunction‐associated steatohepatitis trends as a function of age in people living with HIV
View PublicationAcetylsalicylic acid inhibition of the lipoxygenase pathway: Implications for HIV prevention
To better understand why acetylsalicylic acid (ASA/Aspirin) decreased the proportion of FGT HIV target cells by 35 % by analyzing if ASA reduces inflammation through downregulation of oxylipins.
View PublicationFeasibility of a Randomized, Interventional Pilot Clinical Study of Oral Cannabinoids in People with HIV on Antiretroviral Therapy: CTNPT 028
To report on timeliness to study initiation, enrolment, compliance and retention rates of a prospective, randomized pilot study with participants with HIV, aged ≥18 and on antiretroviral therapy and randomly assigned to cannabidiol (CBD) ± Δ9-tetrahydrocannabinol (THC) capsules for 12 weeks with the primary objective being to assess safety and tolerability.
View Publication